Email updates

Keep up to date with the latest news and content from AACI and BioMed Central.

This article is part of the supplement: Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2012

Open Access Open Badges Meeting abstract

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura

H Chapdelaine1, H Decaluwe12, MC Levasseur1, F De Deist13 and E Haddad12*

Author Affiliations

1 Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada, H3T 1C5

2 Department of Microbiology and Immunology, Université de Montréal, Montréal, Québec, Canada, H3T 1J4

3 Department of Microbiology and Immunology, CHU Sainte-Justine, Montréal, Québec, Canada, H3T 1C5

For all author emails, please log on.

Allergy, Asthma & Clinical Immunology 2012, 8(Suppl 1):A23  doi:10.1186/1710-1492-8-S1-A23

The electronic version of this article is the complete one and can be found online at:

Published:2 November 2012

© 2012 Chapdelaine et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Immune thrombocytopenia purpura (ITP) can co-exist with primary immunodeficiencies. Intravenous immunoglobulin (IGIV) therapy is an effective treatment. Subcutaneous immunoglobulin (SCIG) formulations that can be home-delivered have recently been developed. We describe 2 cases of pediatric ITP associated with hypogammaglobulinemia, treated with SCIG.

Case description

Case 1

A 14-year old male presented with a symptomatic thrombopenia. Infusions of IGIV led to an immediate improvement in platelet count. However, he experienced post-infusion intractable headaches, nausea and vomiting, which recurred after subsequent infusions. Intravenous anti-D therapy resulted in a severe allergic reaction. Short course prednisone protocol was implemented for symptomatic episodes. Preliminary blood work for splenectomy revealed low IgG level. The patient was put on SCIG replacement therapy (116 mg/kg/week). He experienced only one relapse since, which remained corticoresponsive.

Case 2

A 14-year-old male was referred for asymptomatic thrombo-neutropenia. Extensive work-up was normal. He was administered IVIG after which the platelet count quickly normalized. Eighteen months later, he developed monoarthritis and generalized adenopathies. Dominant lymph node biopsy showed reactive lymphoid hyperplasia. The patient started to experience recurrent thrombopenia flare-ups, needing monthly IVIG. Laboratory results indicated low IgM and IgG levels. To prevent further episodes, he received prophylactic monthly IVIG for 6 months before switching to SCIG (135 mg/kg/week). Platelet and also neutrophil levels normalized, which was not achieved with IGIV.

In both patients, SCIG therapy was well-tolerated with no adverse events occurring.


These results suggest that SCIG can be an effective and convenient treatment of pediatric ITP.